{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T01:22:22Z","timestamp":1771464142214,"version":"3.50.1"},"reference-count":90,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","criticalcare.theclinics.com","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Care Clinics"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.ccc.2021.03.012","type":"journal-article","created":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T06:26:51Z","timestamp":1622096811000},"page":"591-604","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Antithrombotic and Antiplatelet Drug Toxicity"],"prefix":"10.1016","volume":"37","author":[{"given":"David B.","family":"Liss","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael E.","family":"Mullins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.ccc.2021.03.012_bib1","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1056\/NEJM197009242831307","article-title":"Warfarin therapy. 1","volume":"283","author":"Deykin","year":"1970","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.ccc.2021.03.012_bib2","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJM198409063111007","article-title":"Warfarin","volume":"311","author":"Wessler","year":"1984","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccc.2021.03.012_bib3","series-title":"Williams hematology","first-page":"1","article-title":"Molecular biology and biochemistry of the coagulation factors and pathways of hemostasis","author":"Bos","year":"2015"},{"issue":"10","key":"10.1016\/j.ccc.2021.03.012_bib4","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1172\/JCI104839","article-title":"Studies on the coumarin anticoagulant drugs: the pharmacodynamics of warfarin in man","volume":"42","author":"O\u2019Reilly","year":"1963","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.ccc.2021.03.012_bib5","author":"Bristol-Myers Squibb Company"},{"issue":"5","key":"10.1016\/j.ccc.2021.03.012_bib6","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1002\/j.1875-9114.1997.tb03782.x","article-title":"A\u00a0review of enzyme induction of warfarin metabolism with recommendations for patient management","volume":"17","author":"Cropp","year":"1997","journal-title":"Pharmacotherapy"},{"issue":"5","key":"10.1016\/j.ccc.2021.03.012_bib7","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/17425255.2019.1604686","article-title":"Pharmacokinetics and pharmacodynamics of oral anticoagulants used in atrial fibrillation","volume":"15","author":"Fawzy","year":"2019","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"5, Supplement","key":"10.1016\/j.ccc.2021.03.012_bib8","doi-asserted-by":"crossref","first-page":"445S","DOI":"10.1378\/chest.114.5_Supplement.445S","article-title":"Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range","volume":"114","author":"Hirsh","year":"1998","journal-title":"Chest"},{"issue":"2 Suppl","key":"10.1016\/j.ccc.2021.03.012_bib9","doi-asserted-by":"crossref","first-page":"e576S","DOI":"10.1378\/chest.11-2305","article-title":"Antithrombotic and thrombolytic therapy for valvular disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Whitlock","year":"2012","journal-title":"Chest"},{"issue":"25","key":"10.1016\/j.ccc.2021.03.012_bib10","doi-asserted-by":"crossref","first-page":"e1159","DOI":"10.1161\/CIR.0000000000000503","article-title":"2017 AHA\/ACC Focused update of the 2014 AHA\/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology\/American heart association Task Force on clinical practice guidelines","volume":"135","author":"Nishimura","year":"2017","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.ccc.2021.03.012_bib11","doi-asserted-by":"crossref","first-page":"e152S","DOI":"10.1378\/chest.11-2295","article-title":"Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Holbrook","year":"2012","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.ccc.2021.03.012_bib12","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s13181-013-0378-8","article-title":"Warfarin overdose: a 25-year experience","volume":"10","author":"Levine","year":"2014","journal-title":"J\u00a0Med Toxicol"},{"issue":"4","key":"10.1016\/j.ccc.2021.03.012_bib13","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.jacc.2005.09.058","article-title":"The risk of hemorrhage among patients with warfarin-associated coagulopathy","volume":"47","author":"Garcia","year":"2006","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.ccc.2021.03.012_bib14","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1053\/j.ajkd.2012.09.012","article-title":"Influence of kidney function on risk of hemorrhage among patients taking warfarin: a cohort study","volume":"61","author":"Limdi","year":"2013","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"10.1016\/j.ccc.2021.03.012_bib15","doi-asserted-by":"crossref","first-page":"233","DOI":"10.14503\/THIJ-17-6430","article-title":"Skin necrosis induced by coumarin congeners","volume":"44","author":"Fred","year":"2017","journal-title":"Tex Heart Inst J"},{"issue":"3","key":"10.1016\/j.ccc.2021.03.012_bib16","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1046\/j.1365-2168.2000.01352.x","article-title":"Warfarin induced skin necrosis","volume":"87","author":"Chan","year":"2000","journal-title":"Br J Surg"},{"issue":"6","key":"10.1016\/j.ccc.2021.03.012_bib17","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/0002-9343(87)90231-2","article-title":"Warfarin-related purple toes syndrome and cholesterol microembolization","volume":"82","author":"Hyman","year":"1987","journal-title":"Am J Med"},{"key":"10.1016\/j.ccc.2021.03.012_bib18","doi-asserted-by":"crossref","first-page":"911","DOI":"10.7326\/0003-4819-55-6-911","article-title":"\u201cPurple toes\u201d: an uncommon sequela of oral coumarin drug therapy","volume":"55","author":"Feder","year":"1961","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.ccc.2021.03.012_bib19","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1080\/00325481.1982.11716064","article-title":"\u201cPurple toes\u201d syndrome","volume":"71","author":"Lebsack","year":"1982","journal-title":"Postgrad Med"},{"issue":"3","key":"10.1016\/j.ccc.2021.03.012_bib20","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1177\/014107688107400312","article-title":"Purple toe syndrome","volume":"74","author":"Akle","year":"1981","journal-title":"J\u00a0R Soc Med"},{"issue":"1","key":"10.1016\/j.ccc.2021.03.012_bib21","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s11239-015-1319-y","article-title":"Guidance for the practical management of warfarin therapy in the treatment of venous thromboembolism","volume":"41","author":"Witt","year":"2016","journal-title":"J\u00a0Thromb Thrombolysis"},{"issue":"5","key":"10.1016\/j.ccc.2021.03.012_bib22","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.chest.2018.07.040","article-title":"Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report","volume":"154","author":"Lip","year":"2018","journal-title":"Chest"},{"issue":"7","key":"10.1016\/j.ccc.2021.03.012_bib23","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1161\/STR.0000000000000069","article-title":"Guidelines for the management of spontaneous intracerebral hemorrhage","volume":"46","author":"Hemphill","year":"2015","journal-title":"Stroke"},{"issue":"9","key":"10.1016\/j.ccc.2021.03.012_bib24","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1016\/j.ajem.2020.05.086","article-title":"A\u00a0review of guidelines on anticoagulation reversal across different clinical scenarios \u2013 is there a general consensus?","volume":"38","author":"Milling","year":"2020","journal-title":"Am J Emerg Med"},{"issue":"2","key":"10.1016\/j.ccc.2021.03.012_bib25","doi-asserted-by":"crossref","first-page":"R76","DOI":"10.1186\/cc12685","article-title":"Management of bleeding and coagulopathy following major trauma: an updated European guideline","volume":"17","author":"Spahn","year":"2013","journal-title":"Crit Care"},{"issue":"11","key":"10.1016\/j.ccc.2021.03.012_bib26","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1161\/CIRCULATIONAHA.113.002283","article-title":"Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study","volume":"128","author":"Sarode","year":"2013","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.ccc.2021.03.012_bib27","doi-asserted-by":"crossref","first-page":"198","DOI":"10.5694\/mja12.10614","article-title":"An update of consensus guidelines for warfarin reversal","volume":"198","author":"Tran","year":"2013","journal-title":"Med J Aust"},{"issue":"11","key":"10.1016\/j.ccc.2021.03.012_bib28","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1161\/CIRCULATIONAHA.113.005107","article-title":"Four-factor prothrombin complex concentrate for urgent reversal of vitamin K antagonists in patients with major bleeding","volume":"128","author":"Quinlan","year":"2013","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.ccc.2021.03.012_bib29","doi-asserted-by":"crossref","first-page":"175","DOI":"10.33176\/AACB-19-00029","article-title":"Superwarfarin (long-acting anticoagulant rodenticides) poisoning: from pathophysiology to laboratory-guided clinical management","volume":"40","author":"Chong","year":"2019","journal-title":"Clin Biochem Rev"},{"key":"10.1016\/j.ccc.2021.03.012_bib30","doi-asserted-by":"crossref","first-page":"607","DOI":"10.15585\/mmwr.mm6721a4","article-title":"Notes from the Field: outbreak of severe illness linked to the vitamin K antagonist brodifacoum and use of synthetic cannabinoids \u2014 Illinois, March\u2013April 2018","volume":"67","author":"Moritz","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"6","key":"10.1016\/j.ccc.2021.03.012_bib31","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1111\/j.1365-2141.2008.07119.x","article-title":"The story of the discovery of heparin and warfarin","volume":"141","author":"Wardrop","year":"2008","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.ccc.2021.03.012_bib33","first-page":"807","article-title":"Heparin and low-molecular-weight heparin","volume":"99","author":"Gray","year":"2008","journal-title":"Thromb Haemost"},{"issue":"10","key":"10.1016\/j.ccc.2021.03.012_bib34","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1056\/NEJM199709043371007","article-title":"Low-molecular-weight heparins","volume":"337","author":"Weitz","year":"1997","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"10.1016\/j.ccc.2021.03.012_bib35","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199105303242206","article-title":"Heparin","volume":"324","author":"Hirsh","year":"1991","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.ccc.2021.03.012_bib36","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2165\/00003495-197612010-00002","article-title":"Antithrombotic drugs: Part I","volume":"12","author":"Gallus","year":"1976","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.ccc.2021.03.012_bib37","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1538-7933.2004.00647.x","article-title":"Is laboratory monitoring of low-molecular-weight heparin therapy necessary? Yes","volume":"2","author":"Harenberg","year":"2004","journal-title":"J\u00a0Thromb Haemost"},{"issue":"3","key":"10.1016\/j.ccc.2021.03.012_bib38","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/0049-3848(91)90141-I","article-title":"Delayed elimination of enoxaparin in patients with chronic renal insufficiency","volume":"63","author":"Cadroy","year":"1991","journal-title":"Thromb Res"},{"issue":"4","key":"10.1016\/j.ccc.2021.03.012_bib39","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/ajh.2830290412","article-title":"Pharmacology and special clinical applications of low-molecular-weight heparins","volume":"29","author":"Harenberg","year":"1988","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.ccc.2021.03.012_bib40","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1111\/j.1538-7836.2004.00739.x","article-title":"Laboratory monitoring of low-molecular-weight heparin therapy","volume":"2","author":"Hirsh","year":"2004","journal-title":"J\u00a0Thromb Haemost"},{"issue":"3","key":"10.1016\/j.ccc.2021.03.012_bib41","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1056\/NEJMcp1411910","article-title":"Heparin-induced thrombocytopenia","volume":"373","author":"Greinacher","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.ccc.2021.03.012_bib42","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1160\/TH13-08-0634","article-title":"Characterisation of the conformational changes in platelet factor 4 induced by polyanions: towards in\u00a0vitro prediction of antigenicity","volume":"112","author":"Brandt","year":"2014","journal-title":"Thromb Haemost"},{"issue":"3","key":"10.1016\/j.ccc.2021.03.012_bib43","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.V72.3.925.bloodjournal723925","article-title":"Heparin-induced thrombocytopenia: laboratory studies","volume":"72","author":"Kelton","year":"1988","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.ccc.2021.03.012_bib44","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/S0002-9343(96)00258-6","article-title":"A\u00a014-year study of heparin-induced thrombocytopenia","volume":"101","author":"Warkentin","year":"1996","journal-title":"Am J Med"},{"issue":"3","key":"10.1016\/j.ccc.2021.03.012_bib45","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.chest.2017.11.039","article-title":"Heparin-induced thrombocytopenia in the critically ill patient","volume":"154","author":"East","year":"2018","journal-title":"Chest"},{"issue":"2 Suppl","key":"10.1016\/j.ccc.2021.03.012_bib46","doi-asserted-by":"crossref","first-page":"e495S","DOI":"10.1378\/chest.11-2303","article-title":"Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of chest physicians evidence-based clinical practice guidelines","volume":"141","author":"Linkins","year":"2012","journal-title":"Chest"},{"issue":"2 Suppl","key":"10.1016\/j.ccc.2021.03.012_bib47","doi-asserted-by":"crossref","first-page":"e24S","DOI":"10.1378\/chest.11-2291","article-title":"Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of chest physicians evidence-based clinical practice guidelines","volume":"141","author":"Garcia","year":"2012","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.ccc.2021.03.012_bib48","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S0022-5223(19)34410-1","article-title":"Evaluation of patients at risk for protamine reactions","volume":"98","author":"Levy","year":"1989","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"issue":"2","key":"10.1016\/j.ccc.2021.03.012_bib49","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/jth.13912","article-title":"Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians","volume":"16","author":"Douxfils","year":"2018","journal-title":"J\u00a0Thromb Haemost"},{"issue":"9","key":"10.1016\/j.ccc.2021.03.012_bib50","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1016\/j.amjmed.2011.02.009","article-title":"Dabigatran falsely elevates point of care international normalized ratio results","volume":"124","author":"DeRemer","year":"2011","journal-title":"Am J Med"},{"issue":"2","key":"10.1016\/j.ccc.2021.03.012_bib51","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s13181-012-0276-5","article-title":"Positive outcome after intentional overdose of dabigatran","volume":"9","author":"Woo","year":"2013","journal-title":"J\u00a0Med Toxicol"},{"issue":"3","key":"10.1016\/j.ccc.2021.03.012_bib52","doi-asserted-by":"crossref","first-page":"286","DOI":"10.3109\/15563650.2015.1126287","article-title":"Dabigatran deliberate overdose: two cases and suggestions for laboratory monitoring","volume":"54","author":"Vlad","year":"2016","journal-title":"Clin Toxicol Phila Pa"},{"issue":"3","key":"10.1016\/j.ccc.2021.03.012_bib53","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/bjh.14371","article-title":"Idarucizumab for dabigatran overdose in a child","volume":"180","author":"Shapiro","year":"2018","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.ccc.2021.03.012_bib54","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1080\/15563650.2016.1187737","article-title":"Idarucizumab for dabigatran overdose","volume":"54","author":"Peetermans","year":"2016","journal-title":"Clin Toxicol Phila Pa"},{"issue":"1","key":"10.1016\/j.ccc.2021.03.012_bib55","first-page":"25","article-title":"Conservative management of dabigatran overdose: case report and review of literature","volume":"5","author":"Gorodetsky","year":"2016","journal-title":"Asia Pac J Med Toxicol"},{"issue":"1","key":"10.1016\/j.ccc.2021.03.012_bib56","doi-asserted-by":"crossref","first-page":"39","DOI":"10.5482\/HAMO-17-03-0015","article-title":"Repeated administration of idarucizumab to a patient with dabigatran overdose","volume":"38","author":"Haj\u0161manov\u00e1","year":"2018","journal-title":"Hamostaseologie"},{"issue":"9","key":"10.1016\/j.ccc.2021.03.012_bib57","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.ajem.2014.04.031","article-title":"An observational case series of dabigatran and rivaroxaban exposures reported to a poison control system","volume":"32","author":"Stevenson","year":"2014","journal-title":"Am J Emerg Med"},{"issue":"3","key":"10.1016\/j.ccc.2021.03.012_bib58","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1177\/1060028013513883","article-title":"Evaluation of dabigatran exposures reported to poison control centers","volume":"48","author":"Conway","year":"2014","journal-title":"Ann Pharmacother"},{"issue":"6","key":"10.1016\/j.ccc.2021.03.012_bib59","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s40262-013-0049-6","article-title":"Pharmacometric characterization of dabigatran hemodialysis","volume":"52","author":"Liesenfeld","year":"2013","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"10.1016\/j.ccc.2021.03.012_bib60","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1053\/j.ajkd.2013.02.361","article-title":"Hemodialysis for the treatment of pulmonary hemorrhage from dabigatran overdose","volume":"62","author":"Chen","year":"2013","journal-title":"Am J Kidney Dis"},{"issue":"9","key":"10.1016\/j.ccc.2021.03.012_bib61","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.2215\/CJN.01570213","article-title":"Extracorporeal therapy for dabigatran removal in the treatment of acute bleeding: a single center experience","volume":"8","author":"Singh","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"issue":"14","key":"10.1016\/j.ccc.2021.03.012_bib62","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1161\/CIRCULATIONAHA.111.029017","article-title":"Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects","volume":"124","author":"Eerenberg","year":"2011","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.ccc.2021.03.012_bib63","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1502000","article-title":"Idarucizumab for dabigatran reversal","volume":"373","author":"Pollack","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.ccc.2021.03.012_bib64","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1111\/jth.13706","article-title":"The recommended dose of idarucizumab may not always be sufficient for sustained reversal of dabigatran","volume":"15","author":"Simon","year":"2017","journal-title":"J\u00a0Thromb Haemost"},{"issue":"3","key":"10.1016\/j.ccc.2021.03.012_bib65","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1080\/15563650.2017.1349911","article-title":"Incomplete dabigatran reversal with idarucizumab","volume":"56","author":"Steele","year":"2018","journal-title":"Clin Toxicol"},{"issue":"8","key":"10.1016\/j.ccc.2021.03.012_bib66","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1002\/phar.2306","article-title":"Intraoperative unfractionated heparin unresponsiveness during endovascular repair of a ruptured abdominal aortic aneurysm following administration of andexanet\u00a0alfa for the reversal of rivaroxaban","volume":"39","author":"Eche","year":"2019","journal-title":"Pharmacotherapy"},{"issue":"4","key":"10.1016\/j.ccc.2021.03.012_bib67","first-page":"390","article-title":"Difficult intraoperative heparinization following andexanet\u00a0alfa administration","volume":"3","author":"Watson","year":"2019","journal-title":"Clin Pract Cases Emerg Med"},{"issue":"3","key":"10.1016\/j.ccc.2021.03.012_bib68","first-page":"261","article-title":"Laboratory monitoring of low-molecular-weight heparin and fondaparinux","volume":"43","author":"Babin","year":"2017","journal-title":"Semin Thromb Hemost"},{"issue":"5","key":"10.1016\/j.ccc.2021.03.012_bib69","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1182\/blood-2018-06-820746","article-title":"Treatment of bleeding complications in patients on anticoagulant therapy","volume":"133","author":"Piran","year":"2019","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.ccc.2021.03.012_bib70","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1161\/01.CIR.0000038501.87442.02","article-title":"Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers","volume":"106","author":"Bijsterveld","year":"2002","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.ccc.2021.03.012_bib71","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/j.1365-2125.2011.03916.x","article-title":"Direct thrombin inhibitors","volume":"72","author":"Lee","year":"2011","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.ccc.2021.03.012_bib72","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1592\/phco.20.4.318.34881","article-title":"The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction","volume":"20","author":"Swan","year":"2000","journal-title":"Pharmacotherapy"},{"issue":"2","key":"10.1016\/j.ccc.2021.03.012_bib73","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1172\/JCI108941","article-title":"Inhibition of platelet prostaglandin synthetase by oral aspirin","volume":"61","author":"Burch","year":"1978","journal-title":"J\u00a0Clin Invest"},{"issue":"2 Suppl","key":"10.1016\/j.ccc.2021.03.012_bib74","doi-asserted-by":"crossref","first-page":"e89S","DOI":"10.1378\/chest.11-2293","article-title":"Antiplatelet drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"Eikelboom","year":"2012","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.ccc.2021.03.012_bib75","first-page":"638","article-title":"Comparison of current platelet functional tests for the assessment of aspirin and clopidogrel response. A review of the literature","volume":"116","author":"Le Quellec","year":"2016","journal-title":"Thromb Haemost"},{"issue":"1","key":"10.1016\/j.ccc.2021.03.012_bib76","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s12028-015-0222-x","article-title":"Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical care Society and Society of Critical Care Medicine","volume":"24","author":"Frontera","year":"2016","journal-title":"Neurocrit Care"},{"issue":"2","key":"10.1016\/j.ccc.2021.03.012_bib77","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.tmrv.2019.01.002","article-title":"Role of platelet transfusion in the reversal of anti-platelet therapy","volume":"33","author":"Nagalla","year":"2019","journal-title":"Transfus Med Rev"},{"issue":"10038","key":"10.1016\/j.ccc.2021.03.012_bib78","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1016\/S0140-6736(16)30392-0","article-title":"Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial","volume":"387","author":"Baharoglu","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ccc.2021.03.012_bib79","first-page":"94","article-title":"Effect of acetylsalicylic acid usage and platelet transfusion on postoperative hemorrhage and activities of daily living in patients with acute intracerebral hemorrhage: clinical article","volume":"118","author":"Li","year":"2013","journal-title":"J\u00a0Neurosurg"},{"issue":"26","key":"10.1016\/j.ccc.2021.03.012_bib80","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1056\/NEJMra2010852","article-title":"Salicylate toxicity","volume":"382","author":"Palmer","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.ccc.2021.03.012_bib81","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/j.2042-7158.1971.tb08598.x","article-title":"Salicylate and enzymes","volume":"23","author":"Smith","year":"1971","journal-title":"J\u00a0Pharm Pharmacol"},{"issue":"4","key":"10.1016\/j.ccc.2021.03.012_bib82","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1067\/mem.2003.128","article-title":"Deleterious effects of endotracheal intubation in salicylate poisoning","volume":"41","author":"Greenberg","year":"2003","journal-title":"Ann Emerg Med"},{"issue":"2","key":"10.1016\/j.ccc.2021.03.012_bib83","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.annemergmed.2015.03.031","article-title":"Extracorporeal treatment for salicylate poisoning: systematic review and recommendations from the EXTRIP Workgroup","volume":"66","author":"Juurlink","year":"2015","journal-title":"Ann Emerg Med"},{"issue":"16","key":"10.1016\/j.ccc.2021.03.012_bib84","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1001\/jama.2010.1543","article-title":"Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis","volume":"304","author":"Mega","year":"2010","journal-title":"JAMA"},{"issue":"15","key":"10.1016\/j.ccc.2021.03.012_bib85","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1007\/s40265-013-0126-z","article-title":"Pharmacology of the new P2Y12 receptor inhibitors: insights on pharmacokinetic and pharmacodynamic properties","volume":"73","author":"Ferri","year":"2013","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.ccc.2021.03.012_bib86","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ahj.2012.03.022","article-title":"Usefulness of the VerifyNow P2Y12 assay to evaluate the antiplatelet effects of ticagrelor and clopidogrel therapies","volume":"164","author":"Jeong","year":"2012","journal-title":"Am Heart J"},{"issue":"5","key":"10.1016\/j.ccc.2021.03.012_bib87","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.jstrokecerebrovasdis.2017.11.033","article-title":"Medication history versus point-of-care platelet activity testing in patients with intracerebral hemorrhage","volume":"27","author":"Maas","year":"2018","journal-title":"J\u00a0Stroke Cerebrovasc Dis"},{"issue":"20","key":"10.1016\/j.ccc.2021.03.012_bib88","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1056\/NEJM198705143162005","article-title":"Dipyridamole","volume":"316","author":"Fitzgerald","year":"1987","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.ccc.2021.03.012_bib89","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/0167-5273(94)90120-1","article-title":"Profound shock resulting from a large dose of dipyridamole","volume":"46","author":"Chen","year":"1994","journal-title":"Int J Cardiol"},{"issue":"4","key":"10.1016\/j.ccc.2021.03.012_bib90","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1055\/s-0030-1267856","article-title":"Review of currently available GP IIb\/IIIa inhibitors and their role in peripheral vascular interventions","volume":"27","author":"Stangl","year":"2010","journal-title":"Semin Interv Radiol"},{"issue":"12","key":"10.1016\/j.ccc.2021.03.012_bib91","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s11883-013-0371-3","article-title":"Pharmacology of antiplatelet agents","volume":"15","author":"Kalra","year":"2013","journal-title":"Curr Atheroscler Rep"}],"container-title":["Critical Care Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749070421000233?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749070421000233?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T02:09:30Z","timestamp":1760062170000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0749070421000233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":90,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S0749070421000233"],"URL":"https:\/\/doi.org\/10.1016\/j.ccc.2021.03.012","relation":{},"ISSN":["0749-0704"],"issn-type":[{"value":"0749-0704","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antithrombotic and Antiplatelet Drug Toxicity","name":"articletitle","label":"Article Title"},{"value":"Critical Care Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccc.2021.03.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}